Skip to main content

Table 1 Patient characteristics

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

CharacteristicLetrozole alone, n = 25Letrozole/bevacizumab, n = 50p value
Age (years)
 Median (range)65 (50.4–86.3)61.4 (50.4–81.9)NSD
Race, n (%)
 White20 (80)42 (84)NSD
 Black3 (12)6 (12)NSD
 Hispanic1 (4)2 (4)NSD
 Others1—Asian (4) 
Clinical tumor stage, n (%)
 IIA9 (36)16 (32)NSD
 IIB7 (28)21 (42)NSD
 IIIA9 (36)8 (16)NSD
 IIIB5 (10)NSD
Nodal status, n (%)
 N09 (36)21 (42)NSD
 N+16 (64)29 (58)NSD
Tumor type, n (%)
 Invasive ductal carcinoma16 (64)29 (58)NSD
 Invasive lobular carcinoma5 (20)13* (26)NSD
 Invasive mixed carcinoma4 (16)7 (14)NSD
 Others1—mucinous (2)NSD
Histologic grade, n (%)
 Grade I6 (24)13 (26)NSD
 Grade II19 (76)29 (58)0.042
 Grade III8 (16)0.025
  1. *Includes one patient with concurrent separate invasive mucinous carcinoma
  2. NSD no significant difference